Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSKN003 in HER2-positive Advanced Colorectal Cancer
NCT07384377Phase 3Not yet recruiting
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Feb 2026
- Primary completion
- Nov 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 3 trial of anbenitamab repodatecan in colorectal cancer (CRC), sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
anbenitamab repodatecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07384377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07384377.